Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation

Auteur(s): Zendaoui, AdnaneLachance, DominicRoussel, ÉliseCouët, JacquesArsenault, Marie
Autre(s) titre(s): Carvedilol treatment for aortic valve regurgitation
Résumé: Background — Aortic regurgitation (AR) is a chronic disease for which there is currently no approved medical treatment. We previously reported in an animal model that β-blockade with metoprolol exerted beneficial effects on left ventricular remodeling and survival. Despite the recent publication of promising human data, β-blockade in chronic AR remains controversial. More data are needed to support this potentially new treatment strategy. We hypothesized that carvedilol might be another safe treatment option in chronic AR, considering its combined β-blocking and α-blocking effects and proven efficacy in patients with established heart failure. Methods and Results — The effects of a 6-month treatment with carvedilol 30 mg/kg/d orally were evaluated in adult Wistar rats with severe AR. Sham-operated and untreated AR animals were used as controls. Carvedilol treatment resulted in less left ventricular hypertrophy and dilatation. Ejection fraction was improved and filling pressures were reduced by carvedilol. β1-Receptor expression was also improved as well as myocardial capillary density. Those beneficial effects were noted despite the presence of drug-induced bradycardia. Conclusions — Carvedilol exerted protective effects against volume-overload cardiomyopathy in this model of aortic valve regurgitation with preserved ejection fraction. These results suggest a protective class effect of β-blockers. Combined with the recent publication of promising human data, our findings support the need to carefully design a prospective study in humans to evaluate the effects of β-blockers in chronic aortic valve regurgitation.
Type de document: Article de recherche
Date de publication: 15 mars 2011
Date de la mise en libre accès: 14 novembre 2017
Version du document: AM
Lien permanent: http://hdl.handle.net/20.500.11794/15842
Ce document a été publié dans: Circulation. Heart failure, Vol. 4 (2), 207–213 (2011)
https://doi.org/10.1161/CIRCHEARTFAILURE.110.958512
Lippincott Williams & Wilkins
Autre version disponible: 10.1161/CIRCHEARTFAILURE.110.958512
21216836
Collection :Articles publiés dans des revues avec comité de lecture

Fichier(s) :
Description TailleFormat 
4.pdf515.43 kBAdobe PDFMiniature
Télécharger
Tous les documents dans CorpusUL sont protégés par la Loi sur le droit d'auteur du Canada.